Device Trial Radar · NCT02358980
Kidney Therapy for Free Light Chain Removal in Patients With Multiple Myeloma & Cast Nephropathy
Last checked: Nov 20, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5
Actual
Start
Feb 18, 2015
Primary completion
Sep 30, 2018
Study completion Sep 30, 2018
Sponsor
- Lead sponsor
- Azienda USL Reggio Emilia - IRCCSGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Feb 9, 2015
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hypothesis: Free light chain (FLC) removal haemodialysis will increase the rate of renal recovery in patients with cast nephropathy, severe renal failure and de novo multiple myeloma. This study will evaluate patients with multiple myeloma and severe renal failure treated with KIDNEY Therapy (previously called SUPRA HFR) to remove free light chains.
Conditions
- Multiple Myeloma
- Cast Nephropathy
- Acute Kidney Injury
Interventions
KIDNEY therapyDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Independence of haemodialysis at 3 months from enrollmentTime frame: 3 months from enrollment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nephrology and Dialysis Unit ASMN IRCCS
Reggio Emilia, Reggio Emilia, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.